8-K: LifeVantage Reports Significant Q4 and FY26 Declines

LifeVantage Corporation announced a substantial year-over-year decrease in revenue and net income for its fourth fiscal quarter and full fiscal year 2026, citing macroeconomic pressures and product sales declines.

Summary

• LifeVantage Corporation reported a 23.1% decrease in fourth-quarter fiscal 2026 revenue to $42.4 million and a 20.1% decrease for the full fiscal year 2026 to $182.6 million.
• Net income per diluted share for Q4 FY26 was $0.10, down from $0.15 in the prior year, and for the full year FY26 was $0.40, down from $0.75.
• Adjusted EBITDA for Q4 FY26 was $2.7 million, a decrease from $4.8 million in Q4 FY25, and for the full year FY26 was $13.7 million, down from $22.1 million.
• The company experienced declines in both the Americas and Asia/Pacific & Europe regions.
• Active accounts, including both consultants and customers, saw a significant decrease of 21.2% year-over-year.
• The company is not issuing formal guidance for fiscal year 2027 due to a recent CEO transition.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to significant revenue and profit declines, coupled with a lack of forward-looking guidance.

Positives

• The company maintained strong gross margins, with Q4 FY26 at 78.0% and full year FY26 at 77.6%.
• The balance sheet remains debt-free.
• The company repurchased approximately $2.0 million of its common shares during fiscal 2026.
• A significant portion ($58.5 million) remains under the $60 million share repurchase program.

Negatives

• Revenue decreased by 23.1% in Q4 FY26 and 20.1% for the full fiscal year 2026.
• Net income per diluted share decreased to $0.10 in Q4 FY26 from $0.15 and to $0.40 for the full year from $0.75.
• Adjusted EBITDA decreased to $2.7 million in Q4 FY26 from $4.8 million and to $13.7 million for the full year from $22.1 million.
• Total active accounts decreased by 21.2% year-over-year.
• Gross profit percentage decreased slightly due to product mix and inventory obsolescence.
• The company is not providing fiscal year 2027 guidance.

Risks

• Deterioration of the global economic and operating environments.
• Impacts from the broader macro-economic environment on order numbers and average order size.
• Lower sales of the MindBody GLP-1 System.
• Inventory obsolescence expenses related to the MindBody GLP-1 System.
• Potential for future declines if strategic initiatives do not yield results.

Future Outlook

The company is not issuing formal guidance for fiscal year 2027 due to a recent transition in the Chief Executive Officer role. The CEO expressed optimism about the company's foundation and competitive advantage, with an early focus on strengthening the brand, building a more relevant consumer proposition, and driving operational excellence.

Management Comments

• "It's a privilege to lead LifeVantage at this stage of its journey and my conviction about this Company is stronger today than when I accepted the role," said Terrence Moorehead, President and Chief Executive Officer.
• "With a differentiated, science-backed platform, strong gross margins and a debt-free balance sheet, our foundation is strong and I believe we have a real competitive advantage."
• "Our early focus will be on strengthening the LifeVantage brand, building a more relevant consumer proposition, and driving operational excellence."
• "Despite the challenges reflected in our recent results, I'm optimistic about what lies ahead. We intend to move forward with a real sense of urgency and look forward to sharing more about our strategy as our work progresses."

Industry Context

StockSavvy.ai notes that the reported declines in revenue and active accounts for LifeVantage align with broader challenges faced by companies in the direct selling and health and wellness sectors, which are sensitive to macroeconomic conditions and shifts in consumer spending and preferences.

Stakeholder Impact

• Shareholders may be concerned by the significant decline in revenue and profitability, potentially impacting stock value.
• Independent consultants and customers may be affected by the decrease in active accounts and potential shifts in product focus or marketing strategies.
• Employees may face uncertainty due to the company's performance and recent CEO transition, although management expresses optimism.

Next Steps

• Strengthen the LifeVantage brand.
• Build a more relevant consumer proposition.
• Drive operational excellence.
• Share more about the company's strategy as work progresses.

Key Dates

Recommendation

The significant decline in financial performance and lack of forward guidance suggest caution. However, the company's debt-free status, strong gross margins, and stated focus on brand and operational improvements provide a basis for holding the stock while awaiting strategic clarity and signs of recovery.

Keywords

health and wellness, nutrigenomics, cellular health, direct selling, supplement, revenue decline, financial results